ImpediMed (ASX:IPD) Insider Purchases A$30,000.00 in Stock

ImpediMed Limited (ASX:IPDGet Free Report) insider Christine Emmanuel-Donnelly bought 1,500,000 shares of the firm’s stock in a transaction on Thursday, February 5th. The stock was bought at an average price of A$0.02 per share, with a total value of A$30,000.00.

ImpediMed Stock Performance

The company has a quick ratio of 6.23, a current ratio of 6.33 and a debt-to-equity ratio of 2.81. The firm has a market cap of $103.31 million, a P/E ratio of -5.27, a P/E/G ratio of -102.50 and a beta of 2.86.

ImpediMed Company Profile

(Get Free Report)

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.

Featured Articles

Receive News & Ratings for ImpediMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImpediMed and related companies with MarketBeat.com's FREE daily email newsletter.